Sumatriptan Succinate Tablets

Awarded Award Notice Posted Jul 25, 2023

Solicitation number: SPE2D223R0003
Agency: Medical Supply Chain Troop Support, Department of Defense
Awarded: Jul 25, 2023 to Golden State Medical Supply, Inc.
Set-aside: No set-aside

Opportunity facts

Contract number: SPE2D223D0009 Federal IDV award
NAICS code: 325412 Pharmaceutical Preparation Manufacturing
PSC: 6505 Drugs And Biologicals
Place of performance: Carole Park Australian Capital Territory 4300 Australia
Points of contact: Jason Wray jason.wray@dla.mil (215) 737-0614

Nancy Fernandez nancy.fernandez@dla.mil (215) 737-4955

Notice details come from SAM.gov. Updated Jul 1, 2026.

About this opportunity

Written by GovTribe AI · Jul 1, 2026

The Defense Logistics Agency Troop Support Medical awarded contract SPE2D223D0009 to Golden State Medical Supply Inc. for sumatriptan succinate tablets on July 25, 2023, with a potential five-year value of $14.9 million.

The contract covers sumatriptan succinate in 25 mg, 50 mg, and 100 mg tablet formulations packaged in bottles of nine tablets. Pricing is firm fixed price, ranging from $3.21 to $3.84 per bottle depending on dosage and contract year. Place of manufacture is AlphaPharm PTY, Ltd. in Australia; packing occurs at Golden State's facility in Camarillo, California. The contract administered by DLA Troop Support Medical Supply Chain in Philadelphia, PA, incorporates Drug Supply Chain Security Act requirements for bar code labeling on unit-of-use and outside containers encoding the National Drug Code, lot number, and expiration date.

Option Year Three (effective July 25, 2026 through July 24, 2027) was exercised as of July 1, 2026. Prior option years were exercised on their respective anniversary dates. The award followed unrestricted competition.

Notice text

5 versions

As posted on SAM.gov.

Update #5 · Latest · Jul 1, 2026

Modification SPE2D223D0009 P00007 posted to announce exercising of Option Year Three (3), effective July 25, 2026 through July 24, 2027.